A Comparison of Imipenem to Ceftazidime With or Without Amikacin as Empiric Therapy in Febrile Neutropenic Patients

Archives of Internal Medicine

Volumn 152, Issue 2, 1992, Pages 283-291

  Rolston, Kenneth V I ^a   Berkey, Peter ^a   Bodey, Gerald P ^a   Anaissie, Elias J ^a   Khardori, Nancy M ^a   Joshi, Jai H ^a   Keating, Michael J ^a   Holmes, Frankie A ^a   Cabanillas, Fernando F ^a   Elting, Linda ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; IMIPENEM; VANCOMYCIN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; DIARRHEA; DRUG EFFICACY; DRUG INFUSION; DRUG MIXTURE; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; REGRESSION ANALYSIS; SEIZURE;

ADOLESCENT; ADULT; AGED; AMIKACIN; ANTIBIOTICS, COMBINED; BACTERIAL INFECTIONS; CEFTAZIDIME; COMPARATIVE STUDY; FEVER; HUMAN; IMIPENEM; MIDDLE AGE; NEOPLASMS; NEUTROPENIA; PROGNOSIS; SUPERINFECTION; SUPPORT, NON-U.S. GOV'T;

EID: 0026590795     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1992.00400140037010     Document Type: Article

References (34)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leucocytes and infections in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
2. Bodey GP. Infection in cancer patients: a continuing association. Am J Med. 1986;81(suppl 1A):11-26.
3. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Rev Infect Dis. 1990;161:381-396.
4. Keting MJ, Bodey GP, Valdivieso M, Rodriguez V. A randomized comparative trial of three aminoglycosides: comparison of continuous infusion of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine. 1979;58:159-170.
5. Wade JL, Schimpff SC, Neuman KA, Fortner CL, Standiford HC, Wiernik PH. Piperacillin or ticarcillin plus amikacin: a double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1981;71:983-990.
6. Winston DJ, Ho WG, Young LS, Hewitt WL, Gale RP. Piperacillin plus amikacin therapy versus carbenicillin plus amikacin therapy in febrile, granulocytopenic patients. Arch Intern Med. 1982;142:1663-1667.
7. Winston DJ, Barner RC, Ho WG, Young LS, Champion RE, Gale RP. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med. 1984;77:442-450.
8. Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ. Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med. 1984;144:1766-1770.
9. Rotstein C, Gmino M, Winkey K, Cesari C, Fenner J. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients. Am J Med. 1988;85(suppl IA):36-39.
10. Fainstein V, Bodey CP, Elting L, et al. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients. J Antimicrob Chemother. 1983;12(suppl A):101-110.
11. Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986;315:552-558.
12. Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Weerts D. Single-drug versus combination empirical therapy for gram-negative bacillary infections in cancer patients with and without granulocytopenia. Antimicrob Agents Chemother. 1984;26:870-875.
13. Bodey GP, Alvarez ME, Jones PG, Rolston KVI, Steelhammer L, Fainstein V. Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother. 1986;30:211-214.
14. Bodey GP, Rolston K, Jones P, Alvarez ME, Fainstein V, Steelhammer L. Imipenem/cilastatin as secondary therapy for infections in cancer patients. J Antimicrob Chemother. 1986;18(suppl E):161-166.
15. Verhagen CS, dePauw B, deWitte T, et al. Randomized prospective trial of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1987;31:191-196.
16. dePauw B, Williams K, deNeeff J, et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1988;28:824-828.
17. Granowetter L, Wells H, Lange BJ. Ceftazidime with or without vancomycin vs cephalothin, carbenicillin and gentamicin as initial therapy of the febrile neutropenic pediatric patient. Pediatr Infect Dis J. 1988;7:165-170.
18. Kramer BS, Ramphal R, Rand KH. Randomized comparison between two ceftazidime-containing regimens and cephalothingentamicin-carbenicillin in febrile granulocytopenic patients. Antimicrob Agents Chemother. 1986;30:64-68.
19. Bodey GP, Valdivieso M, Yap BS. The role of schedule in antibiotic therapy of the neutropenic patient. Infection. 1980;8(suppl B):75-81.
20. Garcia I, Fainstein V, Smith RG, Bodey GP. Multiple-dose pharmacokinetics of ceftazidime in cancer patients. Antimicrob Agents Chemother. 1983;24:141-144.
21. Rolston KVI, LeBlanc B, Gooch G, et al. In-vitro activity of PD-117558—a new quinolone against bacterial isolates from cancer patients. J Antimicrob Chemother. 1989;23:363-371.
22. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, M7-A. Villanova, Pa: National Committee for Clinical Laboratory Standards; 1985.
23. Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med. 1984;144:1845-1851.
24. deJongh CA, Joshi JH, Neuman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med. 1986;80(suppl 5C):96-100.
25. deJongh CA, Joshi JM, Thompson BW, et al. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med. 1986;80:101-111.
26. Anaissie EJ, Fainstein V, Bodey GP, et al. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med. 1988;84:581-589.
27. Bodey GP, Fainstein V, Elting LS, et al. Beta-lactam regimens for the febrile neutropenic patient. Cancer. 1990;65:9-16.
28. Liang R, Yung R, Chau PY, et al. Imipenem/cilastatin as initial therapy for febrile neutropenic patients. J Antimicrob Chemother. 1988;22:765-770.
29. Viscoli C, Van der Auwera P, Meunier F. Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother. 1988;21(suppl C):149-156.
30. Shenep J, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin and amikacin compared with ticarcillin clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med. 1988;319:1053-1058.
31. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988;108:30-35.
32. The EORTC International Antimicrobial Therapy Cooperative Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis. 1991;163:951-958.
33. Rolston KVI, Thirolf P, Ho DH, Bodey GP. Species dependent variability in the susceptibility of coagulasenegative staphylococci to various antimicrobial agents. J Antimicrob Chemother. 1985;16:659-662.
34. The EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987;317:1692-1698.